| Karen L Eshraghi, MD | |
|
5721 Osage Beach Pkwy Ste 100, Osage Beach, MO 65065-3030 | |
| (573) 302-4696 | |
| (573) 302-4698 |
| Full Name | Karen L Eshraghi |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 34 Years |
| Location | 5721 Osage Beach Pkwy Ste 100, Osage Beach, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942299326 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | R8P969 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lake Regional Health System | Osage beach, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Forefront Dermatology | 3779471701 | 474 |
News Archive
Researchers at the University of California, San Diego School of Medicine have identified the motors that move non-infectious prion proteins (PrPC) - found within many mammalian cells - up and down long, neuronal transport pathways.
Hosted by Charité - Universitatsmedizin Berlin, the TrueBrainConnect project aims to systematically study connections between different areas of the brain, and hopes to draw conclusions regarding potential disease patterns.
More children than ever are being admitted to intensive care units in England and Wales but there are fewer staff per bed available to cope with the increase, according to a new report published jointly by the University of Leeds and University of Leicester.
Incyte Corporation announced today positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, involving 46 patients with HER2 positive metastatic breast cancer.
› Verified 2 days ago
| Entity Name | Forefront Dermatology Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891179040 PECOS PAC ID: 3779471701 Enrollment ID: O20150922001275 |
News Archive
Researchers at the University of California, San Diego School of Medicine have identified the motors that move non-infectious prion proteins (PrPC) - found within many mammalian cells - up and down long, neuronal transport pathways.
Hosted by Charité - Universitatsmedizin Berlin, the TrueBrainConnect project aims to systematically study connections between different areas of the brain, and hopes to draw conclusions regarding potential disease patterns.
More children than ever are being admitted to intensive care units in England and Wales but there are fewer staff per bed available to cope with the increase, according to a new report published jointly by the University of Leeds and University of Leicester.
Incyte Corporation announced today positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, involving 46 patients with HER2 positive metastatic breast cancer.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Karen L Eshraghi, MD 801 York St, Manitowoc, WI 54220-4630 Ph: (920) 663-9016 | Karen L Eshraghi, MD 5721 Osage Beach Pkwy Ste 100, Osage Beach, MO 65065-3030 Ph: (573) 302-4696 |
News Archive
Researchers at the University of California, San Diego School of Medicine have identified the motors that move non-infectious prion proteins (PrPC) - found within many mammalian cells - up and down long, neuronal transport pathways.
Hosted by Charité - Universitatsmedizin Berlin, the TrueBrainConnect project aims to systematically study connections between different areas of the brain, and hopes to draw conclusions regarding potential disease patterns.
More children than ever are being admitted to intensive care units in England and Wales but there are fewer staff per bed available to cope with the increase, according to a new report published jointly by the University of Leeds and University of Leicester.
Incyte Corporation announced today positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, involving 46 patients with HER2 positive metastatic breast cancer.
› Verified 2 days ago
John D Despain, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5721 Osage Beach Pkwy Ste 100, Osage Beach, MO 65065 Phone: 573-302-4696 Fax: 573-302-4698 |